Study Details
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Clinicaltrials.gov ID
Astellas Study ID
1948-CL-0101
EudraCT ID
2018-003873-82
Condition
Advanced/Metastatic Cancer
Phase
Phase 1
Age
18 Years - N/A
Sex
Female & Male
Product
ASP1948
Type
Interventional
Trial Dates
Jul 2018 - Mar 2023
Masking
None (Open Label)
Enrollment number
190
A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination with a PD-l inhibitor (Nivolumab or Pembrolizumab) in Subjects with Advanced Solid Tumors
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Norton Cancer Institute
Louisville, United States, 40202
Site TW88602
Taipei, Taiwan, Province of China
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
Omaha, United States, 68310
Site KR82002
Seoul, Republic of Korea
Washington University
St. Louis, United States, 63110
University of Chicago
Chicago, United States, 60637
Site KR82005
Seoul, Republic of Korea
Mary Crowley Cancer Research Center
Dallas, United States, 75230
Site KR82004
Seoul, Republic of Korea
Comprehensive Cancer Centers of Nevada
Las Vegas, United States, 89169
University of Tennessee Medical Center
Knoxville, United States, 37920
Montefiore Medical Center
Bronx, United States, 10461
Virginia Cancer Care Specialist, PC
Fairfax, United States, 22031
Henry-Joyce Cancer Center
Nashville, United States, 37232
Site CA15001
Toronto, Canada
Memorial Sloan Kettering Cancer Center
New York, United States, 10065
Cancer Center at Greater Baltimore Medical
Baltimore, United States, 21153
University of Washington-Seattle Cancer Care Alliance
Seattle, United States, 98109
Icahn School of Medicine at Mount Sinai
New York, United States, 10029
Site KR82001
Seoul, Republic of Korea
Site CA15004
Montreal, Canada
University of Oklahoma
Oklahoma City, United States, 73104
University of Michigan Comprehensive Cancer Center
Ann Arbor, United States, 48109
Sarah Cannon Research Institute – SCRI
Nashville, United States, 37203
Froedtert & The medical college of Wisconsin
Milwaukee, United States, 53226
Oregon Health and Science University
Portland, United States, 97239
The Ohio State University James Cancer Hospital and Solove Research Institute
Columbus, United States, 43210
Site KR82006
Seoul, Republic of Korea
Site KR82003
Seoul, Republic of Korea
Yale Center for Clinical Investigation
New Haven, United States, 06520-8028
Augusta University
Augusta, United States, 30912
UPMC- Hillman Cancer Center
Pittsburgh, United States, 15232
Site KR82007
Seoul, Republic of Korea
University of South Carolina
Charleston, United States, 29425
Dartmouth Hitchcock Med Center
Lebanon, United States, 03756
South Texas Accelerated Research Therapeutics
San Antonio, United States, 78229
Site CA15002
Edmonton, Canada
Women And Infants
Providence, United States, 02905
Site ES34001
Avila, Spain
Site ES34003
Cataluna, Spain
Site ES34004
Cataluna, Spain
Site ES34005
Valencia, Spain
Site ES34007
Madrid, Spain
Site ES34009
Madrid, Spain
Site ES34012
Madrid, Spain
Site GB44001
Glasgow, United Kingdom
Site TW88601
Taipei, Taiwan, Province of China
Site ES34010
Barcelona, Spain
Site JP81001
Tokyo, Japan
Site JP81002
Chiba, Japan
Site IT39006
Modena, Italy
Site IT39008
Milano, Italy
Site IT39003
Meldola, Italy
Site ES34002
Barcelona, Spain
Huntsman Cancer Institute
Salt Lake City, United States, 84112
Site ES34006
Barcelona, Spain
Site ES34014
Barcelona, Spain
Site CA15006
Toronto, Canada
Site IT39001
Monza, Italy
Site IT39005
Milano, Italy
Site IT39007
Milano, Italy
Site PT35104
Porto, Portugal
Site PT35105
Braga, Portugal
Site GB44003
Sheffield, United Kingdom
Site GB44004
Newcastle upon Tyne, United Kingdom
Site GB44006
Manchester, United Kingdom
Mayo clinic
Phoenix, United States, 85259
Site TW88603
Tainan, Taiwan, Province of China
Henry Ford Health System
Detroit, United States, 48202
The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website
© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.
POWERED BY:
